GenScript ProBio and Curocell have announced a strategic partnership to advance the development of next-generation CAR-T therapy. The collaboration aims to address the increasing demand for viral vectors used in gene therapy, particularly CAR-T therapy. Viral vectors are essential in delivering genetic material for efficient drug delivery. The shortage of facilities producing viral vectors has led to delays in the development of gene therapies. By joining forces, GenScript ProBio and Curocell intend to strengthen their cooperation in research and development, production, and clinical trials of viral vectors for CAR-T therapy.
CAR-T therapy, short for Chimeric Antigen Receptor-T cell therapy, is a cutting-edge cancer immunotherapy that modifies a patient’s immune T cells to express antigens targeting cancer cells. These modified cells are then reintroduced into the patient, effectively destroying the cancer. CAR-T therapy has shown promising results, often achieving complete remission even in patients with terminal leukemia.
Curocell, a Korean-based CAR-T treatment specialist, is at the forefront of CAR-T cell therapy development. The company focuses on overcoming the limitations of existing cancer immunotherapies to treat various cancer types. Collaborating with top experts in CAR-T technology and biopharmaceutical development, as well as major Korean hospitals, Curocell aims to systematically develop new CAR-T cell therapies. It has obtained regulatory approval for CAR-T clinical trials and possesses a state-of-the-art commercial GMP facility for manufacturing its products.
GenScript ProBio, a global contract research organization and contract development and manufacturing organization, specializes in the development of high-quality one-stop manufacturing processes for viral vectors in the field of cell and gene therapy. The company operates globally, supporting clients across the United States, Europe, and Asia. With multiple regional offices and a well-established network, the company has obtained approval for investigational new drug applications from over 60 countries worldwide.
The partnership between GenScript ProBio and Curocell is expected to deepen collaboration and expand the development of CAR-T therapy not only in Korea but on a global scale. GenScript ProBio Chairman Patrick LIU expressed his excitement about the partnership, emphasizing the potential for global CAR-T therapy development. Curocell CEO Gunsoo Kim echoed this sentiment, highlighting the opportunity to establish a stable cooperative relationship throughout the entire process, from development to commercialization.
The collaboration between these two companies represents a significant step forward in advancing CAR-T therapy and addressing the shortage of viral vector facilities. By pooling their expertise and resources, they aim to make a substantial impact in the field of cancer immunotherapies. With CAR-T therapy showing great promise in treating various cancers, the partnership between GenScript ProBio and Curocell is poised to contribute to the development of next-generation therapies that could revolutionize cancer treatment.
